this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

NameS-bicalutamide
Identifiers(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide
FormulaC18 H14 F4 N2 O4 S
Molecular Weight430.37 g/mol
TypeNON-POLYMER
Isomeric SMILESC[C@@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F
InChIInChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m1/s1
InChIKeyLKJPYSCBVHEWIU-QGZVFWFLSA-N

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count1
Chiral AtomsC16
Bond Count44
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01128 Different stereochemistry
NameBicalutamide
Groupsapproved
DescriptionBicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.
SynonymsCasodex
Brand Names
  • Accel-bicalutamide Tablets USP
  • Ach-bicalutamide
  • Act Bicalutamide
  • Ag-bicalutamide
  • Apo-bicalutamide
Affected OrganismHumans and other mammals
IndicationFor treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
PharmacologyBicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Mechanism of actionBicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Route of administrationOral
Categories
  • Amides
  • Androgen Antagonists
  • Anti-Androgens
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
ATC-CodeL02BB03
AHFS-Code10:00.00
CAS number90357-06-5

Drug Targets

NameSequence SearchPharmacological ActionActions
Androgen receptorMEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPP...yesantagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682